Evaluation of mitoguazone in patients with refractory chronic lymphocytic leukemia: a phase II study (P-H482) of the Eastern Cooperative Oncology Group

Mitoguazone is a unique antitumor agent that interferes with polyamine synt hesis that has been reported to have activity against AIDS-related malignan t lymphoma. We, therefore, tested this agent for activity against chronic l ymphocytic leukemia (CLL) in this phase II study. Mitoguazone, 500 mg/M-2 w as given intravenously weekly to 13 patients with relapsed or refractory, p reviously treated Rai stages 2-4, CLL. There were no complete or partial re sponses as judged by standard criteria. Toxicity was acceptable. Mitoguazon e in the dose and schedule employed in this study has no significant activi ty as a single agent in patients with relapsed or refractory CLL.